Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age

The Pfizer-BioNTech and Moderna COVID-19 vaccines are mRNA vaccines that were initially authorized by Health Canada for use in individuals 16 and 18 years of age and older, respectively, in December 2020. On May 5, 2021, Health Canada expanded the Interim Order authorization for the Pfizer-BioNTech COVID-19 vaccine to also include adolescents 12 to 15 years of age based on clinical trial results in this age group.

Données et ressources

Info additionnelle

Champ	Valeur
Dernière modification	avril 17, 2026, 18:48 (TU)
Créé le	avril 17, 2026, 18:48 (TU)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2021-08-27 00:00:00
open_canada_keywords	{"fr": ["Recommandation", "utilisation", "vaccins", "ARNm", "contre", "la COVID-19", "chez", "adolescents", "12 à 17 ans", "COVID-19", "vaccination", "Pfizer-BioNTech", "Moderna", "vaccins", "immunisation", "mesures", "santé", "publique", "MSP", "document", "orientation", "système", "santé", "santé publique", "autorités", "santé", "pandémie", "coronavirus"], "en": ["COVID-19", "COVID", "vaccination", "Pfizer-BioNTech", "Moderna", "vaccines", "immunization", "public", "health", "measures", "PHMs", "guidance", "document", "healthcare", "system", "public health", "health", "authorities", "pandemic", "coronavirus", "Recommendation", "use", "mRNA", "vaccines", "adolescents", "12 to 17", "years of age"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Recommandation sur l’utilisation des vaccins à ARNm contre la COVID-19 chez les adolescents de 12 à 17 ans
update_frequency	unknown